Related Experiment Videos
Off-target effects by siRNA can induce toxic phenotype
Yuriy Fedorov1, Emily M Anderson, Amanda Birmingham
1Dharmacon Research, Lafayette, CO 80026, USA. fedorov@dharmacon.com
Summary
Some small inhibitory RNAs (siRNAs) can cause cell death independently of their intended targets. Chemical modifications and a specific RNA motif (UGGC) can mitigate this toxicity, improving siRNA safety.
Area of Science:
- Molecular Biology
- RNA Interference Therapeutics
Background:
- Microarray studies suggest RNA interference (RNAi) can cause off-target gene modulation.
- The phenotypic consequences of these off-target effects remain largely unknown.
Purpose of the Study:
- To investigate whether off-target RNA interference (RNAi) can lead to observable phenotypic changes, specifically in cell viability.
- To identify factors contributing to siRNA-induced toxicity and explore mitigation strategies.
Main Methods:
- Screening of randomly selected small inhibitory RNAs (siRNAs) for effects on cell viability.
- Assessment of toxicity dependence on an intact RNA interference pathway.
- Chemical modification of siRNAs to reduce off-target effects.
- Sequence analysis of toxic and non-toxic siRNA duplexes to identify sequence motifs associated with toxicity.
Main Results:
- A subset of siRNAs induced significant changes in cell viability in a target-independent manner.
- This observed toxicity was dependent on a functional RNA interference (RNAi) pathway.
- Chemical modifications known to reduce off-target effects also eliminated siRNA-induced toxicity.
- A strong correlation was found between siRNA toxicity and the presence of a UGGC motif in the guide strand (RISC-entering strand).
Conclusions:
- Small inhibitory RNAs (siRNAs) can elicit measurable phenotypic outcomes, such as toxicity, through off-target effects.
- The UGGC motif in the siRNA guide strand is a key determinant of this toxicity.
- Chemical modifications represent a viable strategy to mitigate undesirable off-target phenotypes and enhance the safety of RNAi-based therapeutics.